Comparing of Regeneron Pharmaceuticals Inc. (REGN) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA)

We will be comparing the differences between Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA) as far as analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regeneron Pharmaceuticals Inc. 331 1.99 81.71M 20.54 14.84
Idera Pharmaceuticals Inc. 2 0.00 20.28M -1.86 0.00

In table 1 we can see Regeneron Pharmaceuticals Inc. and Idera Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 has Regeneron Pharmaceuticals Inc. and Idera Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals Inc. 24,706,700.53% 29.2% 21.4%
Idera Pharmaceuticals Inc. 868,671,292.73% -72.6% -63.5%

Volatility & Risk

A 1.15 beta indicates that Regeneron Pharmaceuticals Inc. is 15.00% more volatile compared to Standard and Poor’s 500. Idera Pharmaceuticals Inc. on the other hand, has 2.39 beta which makes it 139.00% more volatile compared to Standard and Poor’s 500.


Regeneron Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 4.6 and 4 respectively. The Current Ratio and Quick Ratio of its competitor Idera Pharmaceuticals Inc. are 9.8 and 9.8 respectively. Idera Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Regeneron Pharmaceuticals Inc.

Analyst Recommendations

Recommendations and Ratings for Regeneron Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Regeneron Pharmaceuticals Inc. 0 7 1 2.13
Idera Pharmaceuticals Inc. 0 0 1 3.00

$357.88 is Regeneron Pharmaceuticals Inc.’s consensus price target while its potential downside is -3.27%. Competitively the consensus price target of Idera Pharmaceuticals Inc. is $7, which is potential 286.74% upside. The data from earlier shows that analysts view suggest that Idera Pharmaceuticals Inc. seems more appealing than Regeneron Pharmaceuticals Inc.

Insider & Institutional Ownership

Institutional investors owned 73.9% of Regeneron Pharmaceuticals Inc. shares and 44.7% of Idera Pharmaceuticals Inc. shares. About 20% of Regeneron Pharmaceuticals Inc.’s share are owned by insiders. On the other hand, insiders owned about 0.1% of Idera Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Regeneron Pharmaceuticals Inc. -2.83% -3.73% -10.57% -27.42% -17.97% -18.4%
Idera Pharmaceuticals Inc. 5.47% 3.45% -8.47% 1.89% -58.78% -2.53%

For the past year Idera Pharmaceuticals Inc. has weaker performance than Regeneron Pharmaceuticals Inc.


Regeneron Pharmaceuticals Inc. beats Idera Pharmaceuticals Inc. on 7 of the 13 factors.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.